NASDAQ:ACRS
Aclaris Therapeutics Stock News
$1.17
-0.0500 (-4.10%)
At Close: Apr 24, 2024
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
11:00am, Tuesday, 27'th Sep 2022 GlobeNewswire Inc.
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammato
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Tuesday, 30'th Aug 2022
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
11:00am, Thursday, 25'th Aug 2022 GlobeNewswire Inc.
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammator
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
12:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
09:47am, Wednesday, 03'rd Aug 2022
Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
09:15pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy
04:00pm, Friday, 15'th Jul 2022 Zacks Investment Research
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy
01:46pm, Friday, 15'th Jul 2022
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Philips (PHG) Expands AI Portfolio With SmartSpeed Solution
03:43pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
01:40pm, Friday, 08'th Jul 2022 Zacks Investment Research
Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
11:38am, Friday, 08'th Jul 2022
Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Aclaris Therapeutics Expands Leadership Team
11:00am, Monday, 27'th Jun 2022 GlobeNewswire Inc.
WAYNE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammator
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
01:40pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?
12:20pm, Monday, 20'th Jun 2022 Zacks Investment Research
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?
10:06am, Monday, 20'th Jun 2022
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th
